Multicenter, Open-label, Randomized, Uncontrolled Study to Evaluate Inhibition of Ovulation of Two Transdermal Patch Formulations Containing 0.55 mg EE and Either 1.05 or 2.1 mg GSD in Healthy Young Female Vol. Over a Period of 3 Treatment Cycles.

Trial Profile

Multicenter, Open-label, Randomized, Uncontrolled Study to Evaluate Inhibition of Ovulation of Two Transdermal Patch Formulations Containing 0.55 mg EE and Either 1.05 or 2.1 mg GSD in Healthy Young Female Vol. Over a Period of 3 Treatment Cycles.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2014

At a glance

  • Drugs Ethinylestradiol/gestodene (Primary)
  • Indications Pregnancy
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 05 Jun 2009 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 05 Jun 2009 Planned end date changed from 1 May 2009 to 1 Feb 2009 as reported by ClinicalTrials.gov.
    • 28 Jan 2009 Actual patient numbers (13) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top